cis-cyclopropane-1,2-diamine dihydrochloride

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-cyclopropane-1,2-diamine dihydrochloride
• 英文别名: cis-1,2-Cyclopropanediamine hydrochloride；(1R,2S)-cyclopropane-1,2-diamine;hydrochloride
• 化学式: C₃H₈N₂*2ClH
• 分子量: 145.032
• InChiKey: KAHCAWZDKPJMKI-JZXMGJPMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.53
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  二碳酸二叔丁酯 、 cis-cyclopropane-1,2-diamine dihydrochloride 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 以77%的产率得到(+/-)-(cis)-N,N'-bis(tert-butyloxycarbonyl)-1,2-cyclopropanediamine
  参考文献：
  名称：

  Benzamides derived from 1,2-diaminocyclopropane as novel ligands for human D 2 and D 3 dopamine receptors

  摘要：

  Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diamino cyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D-2 receptors, recombinant human hD(2) and hD(3) receptors expressed in CHO cells and rat, cortical 5-HT3 and striatal 5-HT4 receptors. The cis and trans isomers of the derivatives were isolated and characterised. The results demonstrated the superiority of the cis conformers over the trans conformers in dopamine receptor binding assays (K-i hD(2) = 13.4 and 6.9 nM and K-i hD(3) = 17.7 and 4.5 nM for the cis-3b and cis-3f compounds, respectively; K-i hD(2) = 816 and >1000 nM and K-i hD(3) = 469 and >1000 nM for the corresponding trans-3b and trans-3f compounds respectively). The cis compounds are folded: the benzamide group and the basic nitrogen atom were in a syn relationship. Compound 3f can be superimposed with a conformation of the tropane derivative, BRL 25594, having the benzyl group in an axial position to give a suitable fit, indicating that both compounds may have a common binding site in the dopamine receptor. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00281-3
• 作为产物：
  描述：

  cis-1,2-cyclopropanedicarboxylic acid 在 sodium azide 、 五氯化磷 作用下， 以 甲苯 为溶剂， 反应 32.0h， 生成 cis-cyclopropane-1,2-diamine dihydrochloride
  参考文献：
  名称：

  Benzamides derived from 1,2-diaminocyclopropane as novel ligands for human D 2 and D 3 dopamine receptors

  摘要：

  Benzamides (3a-f) derived from 4-amino-5-chloro-2-methoxybenzoic acid and either cis or trans 1,2-diamino cyclopropane were synthesised and were evaluated in binding assays employing, bovine striatal D-2 receptors, recombinant human hD(2) and hD(3) receptors expressed in CHO cells and rat, cortical 5-HT3 and striatal 5-HT4 receptors. The cis and trans isomers of the derivatives were isolated and characterised. The results demonstrated the superiority of the cis conformers over the trans conformers in dopamine receptor binding assays (K-i hD(2) = 13.4 and 6.9 nM and K-i hD(3) = 17.7 and 4.5 nM for the cis-3b and cis-3f compounds, respectively; K-i hD(2) = 816 and >1000 nM and K-i hD(3) = 469 and >1000 nM for the corresponding trans-3b and trans-3f compounds respectively). The cis compounds are folded: the benzamide group and the basic nitrogen atom were in a syn relationship. Compound 3f can be superimposed with a conformation of the tropane derivative, BRL 25594, having the benzyl group in an axial position to give a suitable fit, indicating that both compounds may have a common binding site in the dopamine receptor. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00281-3

文献信息

• An Efficient and Improved Process for the Scale-up Preparation of cis- Cyclopropanediamine Dihydrochloride
  作者：Fan Wang、Xiao-Ying Xu、Fei-Ying Wang、Lin Peng、Yong Zhang、Liang-Liang Wang、Li-Xin Wang

  DOI：10.2174/1570178612666150907204813

  日期：2015.11.2

  the preparation of cis-cyclopro panediamine dihydrochloride was developed in a 100 g scale. The key step in the process is the preparation of ciscyclopropane- 1, 2-dicarboxylic acid from a mixture of cis- and trans- isomers by the formation of cyclic acidic anhydride. The whole process and all of the procedures are economical, industrially reliable and easily scaled up.

  以100克规模开发了一种有效且改进的制备顺式环丙戊二胺二盐酸盐的方法。该方法的关键步骤是通过形成环酸酐，由顺式和反式异构体的混合物制备顺式环丙烷-1，2-二羧酸。整个过程和所有过程都是经济的，工业上可靠的并且易于扩大规模。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20050245565A1

  公开（公告）日：2005-11-03

  A compound represented by the general formula (1): Q 1 -Q 2 -T 0 -N(R 1 )-Q 3 -N(R 2 ) -T 1 -Q 4 (1) wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 is a group in which Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T 0 and T 1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  一种化合物，其通式为（1）：Q1-Q2-T0-N（R1）-Q3-N（R2）-T1-Q4（1），其中R1和R2为氢原子或类似物；Q1为饱和或不饱和的5-或6-成员环烃基，可能被取代，或类似物；Q2为单键或类似物；Q3为其中Q5为具有1至8个碳原子的烷基或类似物的基团；T0和T1为羰基基团或类似物；其盐、溶剂化合物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固。
• Ethylenediamine derivatives
  申请人：——

  公开号：US20040122063A1

  公开（公告）日：2004-06-24

  The invention relates a compound represented by the formula (1): Q 1 -Q 2 -C(═O)—N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) wherein R 1 and R 2 represent H or the like; Q 1 represents an aromatic ring, heterocyclic ring or the like; Q 2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q 3 represents a group 1 or the like, Q 4 represents an aromatic ring, heterocyclic ring or the like; and T 1 represents —CO— or —SO 2 —, and a medicine which comprises the compound and is useful for thrombosis and embolism.

  本发明涉及一种由式（1）表示的化合物：Q1-Q2-C(═O)—N(R1)-Q3-N(R2)-T1-Q4(1)，其中R1和R2代表H或类似物；Q1代表芳香环，杂环或类似物；Q2代表单键，芳香环，杂环或类似物；Q3代表群1或类似物，Q4代表芳香环，杂环或类似物；T1代表—CO—或—SO2—，以及包含该化合物并对治疗血栓和栓塞有用的药物。
• ETHYLENEDIAMINE DERIVATIVES
  申请人：YOSHINO Toshiharu

  公开号：US20090227789A1

  公开（公告）日：2009-09-10

  The invention relates a compound represented by the formula (1): Q 1 -Q 2 -C(═O)—N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 (1) wherein R 1 and R 2 represent H or the like; Q 1 represents an aromatic ring, heterocyclic ring or the like; Q 2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q 3 represents a group or the like, Q 4 represents an aromatic ring, heterocyclic ring or the like; and T 1 represents —CO— or —SO 2 —, and a medicine which comprises the compound and is useful for thrombosis and embolism.

  本发明涉及一种由公式(1)表示的化合物： Q1-Q2-C(═O)-N(R1)-Q3-N(R2)-T1-Q4(1) 其中R1和R2表示H或类似物; Q1表示芳香环、杂环或类似物; Q2表示单键、芳香环、杂环或类似物; Q3表示基团或类似物，Q4表示芳香环、杂环或类似物; T1表示-CO-或-SO2-，以及包含该化合物的药物，用于治疗血栓和栓塞。
• DIAMINE DERIVATIVES
  申请人：Ohta Toshiharu

  公开号：US20090270446A1

  公开（公告）日：2009-10-29

  The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.

  本发明涉及抑制激活的血液凝血因子X并具有抗凝作用的二胺化合物及其用于治疗基于血栓栓塞的各种疾病的用途。